Amoxicilina-Ácido Clavulánico Dosing Guidelines

Introduction to Dosing

• The American Academy of Otolaryngology-Head and Neck Surgery recommends amoxicilina-ácido clavulánico as a first-line antibiotic for various respiratory infections, with specific dosing based on age and type of infection 1, 2

Adult Dosing

• For adults with mild to moderate infections, the standard dose is 500 mg of amoxicilina/125 mg of ácido clavulánico every 8 hours for 7-10 days 2
• For respiratory infections caused by resistant pathogens, a high dose of 2 g of amoxicilina/125 mg of ácido clavulánico twice daily is recommended 1, 3
• High-dose amoxicilina-ácido clavulánico is indicated in adults with recent antibiotic use, close contact with treated individuals, failed previous antibiotic therapy, infection during prophylaxis, close contact with children in daycare, smokers or exposure to smokers, high prevalence of resistant bacteria, moderate to severe infections, frontal or sphenoidal sinusitis, history of recurrent infections, comorbidities, immunocompromised status, or age over 65 1

Pediatric Dosing

• For children with uncomplicated infections, the standard dose is 45 mg/kg/day of amoxicilina with 6.4 mg/kg/day of ácido clavulánico divided into 2 doses 4
• For children with specific risk factors, such as age under 2, attendance at daycare, recent antibiotic treatment, or pneumonia not responding to amoxicilina alone, a high dose of 80-90 mg/kg/day of amoxicilina with 6.4 mg/kg/day of ácido clavulánico divided into 2 doses is recommended 4, 5, 6

Indications by Pathology

• For acute bacterial sinusitis, adults should receive amoxicilina as first-line treatment, except in cases with risk factors, where high-dose amoxicilina-ácido clavulánico is recommended 1, 2
• For children with acute bacterial sinusitis, standard amoxicilina dosing is recommended as first-line treatment, with high-dose amoxicilina-ácido clavulánico for those with risk factors 4
• Treatment duration for sinusitis is 5-7 days, which is as effective as 10 days in most cases 1
• For non-severe childhood pneumonia, first-line treatment is amoxicilina 50 mg/kg in 2 divided doses for 5 days, with high-dose amoxicilina-ácido clavulánico as second-line treatment if amoxicilina fails 5, 6

Alternative Treatments

• For patients allergic to penicillin, alternative treatments include doxycycline or respiratory fluoroquinolones (levofloxacin or moxifloxacin) in adults, and clindamycin plus a third-generation oral cephalosporin in children with non-type I penicillin allergy 1

Amoxicillin and Clavulanic Acid Treatment Guidelines

Adult Dosing Guidelines

• The standard dosage for Amoxiclave 625 in adults is one tablet (500 mg amoxicillin/125 mg clavulanic acid) three times daily for 14 days for most respiratory infections, as recommended by the Thorax guideline 7
• Treatment duration varies by condition but is typically 14 days for bronchiectasis and respiratory infections, according to the Thorax guideline 7

Specific Indications and Dosing

Respiratory Infections

• For bronchiectasis exacerbations with beta-lactamase producing Haemophilus influenzae: 625 mg three times daily for 14 days, as recommended by the Thorax guideline 7
• For acute bacterial sinusitis in adults with risk factors (recent antibiotic use, treatment failure): 625 mg three times daily for 5-7 days, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery guideline 8

Pediatric Dosing

• For children with risk factors or more severe infections: 80-90 mg/kg/day of amoxicillin with 6.4 mg/kg/day of clavulanic acid divided into 2 doses, as recommended by The Lancet Infectious Diseases guideline 9
• For non-severe childhood pneumonia where amoxicillin has failed: high-dose amoxicillin-clavulanic acid (80-90 mg/kg/day amoxicillin component) for 5 days, as recommended by The Lancet Infectious Diseases guideline 9

Antimicrobial Spectrum

• Amoxicillin-clavulanic acid is also effective against beta-lactamase producing Staphylococcus aureus (MSSA), as reported by the Thorax guideline 7

Amoxicillin-Clavulanate Dosing for Children with Respiratory Infections

Indications for High-Dose Regimen

• The American Academy of Pediatrics recommends high-dose amoxicillin-clavulanate for children who attend daycare, as they are at higher risk of resistant infections 10
• High-dose amoxicillin-clavulanate is recommended for children with recent antibiotic treatment within the previous 30 days, as they are at higher risk of resistant infections 11, 10
• The American Academy of Pediatrics recommends high-dose amoxicillin-clavulanate for areas with high prevalence of penicillin-resistant Streptococcus pneumoniae (>10%) 10
• High-dose amoxicillin-clavulanate is recommended for children with concurrent conjunctivitis, as it provides coverage for Moraxella catarrhalis 11
• The American Academy of Pediatrics recommends high-dose amoxicillin-clavulanate when coverage for Moraxella catarrhalis is desired 11

Adverse Effects

• The 14:1 ratio of amoxicillin to clavulanate in the high-dose formulation is less likely to cause diarrhea than other amoxicillin-clavulanate preparations, according to the American Academy of Pediatrics 11

Amoxicillin-Clavulanate Treatment Guidelines

Introduction to Amoxicillin-Clavulanate Dosage

• The recommended dosage of amoxicillin-clavulanate for bacterial infections varies by patient age, infection type, and severity, with standard adult dosing being 875/125 mg twice daily or 500/125 mg three times daily for most infections, and pediatric dosing based on weight at 45-90 mg/kg/day of the amoxicillin component 12

Adult and Pediatric Dosing

• For animal or human bite infections, amoxicillin-clavulanate 875/125 mg twice daily is recommended 12

Duration of Therapy

• For adults with uncomplicated acute bacterial rhinosinusitis (ABRS), a 5-7 day course is recommended 13
• For children with ABRS, a longer treatment duration of 10-14 days is recommended 13

Clinical Advantages and Considerations

• For empiric treatment of ABRS, amoxicillin-clavulanate is preferred over amoxicillin alone in both adults (weak recommendation) and children (strong recommendation) 13
• Routine coverage for S. aureus (including MRSA) during initial empiric therapy of ABRS is not recommended 13

Amoxicilina-Ácido Clavulánico Treatment Guidelines

Patient Factors Influencing Dosage

• The American Academy of Otolaryngology-Head and Neck Surgery recommends a high dose of 2000 mg/125 mg every 12 hours for patients with recent antibiotic use in the last 4-6 weeks 14, 15
• The American Academy of Otolaryngology-Head and Neck Surgery suggests a high dose for patients with moderate to severe disease 15
• For areas with high prevalence of Streptococcus pneumoniae resistant to penicillin (>10%), a high dose is recommended 15

Alternative Therapies

• The American Academy of Otolaryngology-Head and Neck Surgery recommends 1 gram of ceftriaxone intramuscularly or intravenously daily for 5 days as an alternative therapy for patients who cannot tolerate oral medication or require initial parenteral therapy 15

Pediatric Considerations

• The maximum dose of amoxicilina is 4000 mg/day 16
• For children with risk factors, a high dose of 80-90 mg/kg/day of amoxicilina with 6.4 mg/kg/day of ácido clavulánico is recommended 17

Reevaluation and Treatment Duration

• If there is no improvement after 72 hours, consider changing the antibiotic or reevaluating the diagnosis with cultures, computed tomography, or endoscopy 14, 15

Amoxicillin-Clavulanate Dosing Considerations for Respiratory Infections

Special Considerations for High-Dose Therapy

• The American Academy of Otolaryngology-Head and Neck Surgery suggests that risk factors requiring high-dose therapy include antibiotic use in the previous 4-6 weeks, with a predicted clinical efficacy of high-dose amoxicillin-clavulanate being 90-92% in both adults and children 18
• In areas with a high prevalence of penicillin-resistant S. pneumoniae (>10%), the American Academy of Otolaryngology-Head and Neck Surgery recommends always using high-dose formulations, with a predicted clinical efficacy of 90-92% in both adults and children 18

Co-Amoxiclav Dosing for Adult Bacterial Infections

Standard Adult Dosing Regimens

• The Thorax journal recommends a dose of 625 mg (500 mg amoxicillin/125 mg clavulanate) three times daily for respiratory tract infections without risk factors 19
• For non-severe pneumonia, the Thorax journal suggests a dose of 625 mg three times daily or 875 mg/125 mg twice daily for 7-10 days 19

Administration Guidelines

• The Thorax journal recommends switching from IV to oral formulation as soon as clinically appropriate 19

Specific Infection Types and Durations

• For hospital-treated severe pneumonia requiring IV therapy, the Thorax journal recommends a dose of 1.2 g three times daily IV 19

Amoxicillin-Clavulanate Dosing for Adult Ear Infections

Treatment Duration

• The American Academy of Allergy and Clinical Immunology recommends continuing treatment for 7 days after symptom resolution to ensure complete eradication 20
• The total course of treatment typically ranges from 10-14 days for complete resolution 20

Clinical Efficacy Data

• The American Academy of Otolaryngology-Head and Neck Surgery reports that high-dose amoxicillin-clavulanate (2000 mg/125 mg or 4000 mg/250 mg daily) demonstrates superior outcomes with 90-92% predicted clinical efficacy versus 83-88% for standard-dose amoxicillin 21
• Using high-dose amoxicillin-clavulanate leads to lower treatment failure rates and reduces the risk of promoting antimicrobial resistance, as standard-dose amoxicillin-clavulanate has treatment failure rates of 20-25% when risk factors for resistant organisms are present 21

Reassessment Protocol

• The American Academy of Allergy and Clinical Immunology suggests considering imaging (CT scan) for complicated sinusitis if no improvement or worsening occurs after 72 hours 20

Augmentin Dosing Guidelines

Weight-Based Dosing Threshold

• For patients weighing over 40 kg, such as a 41 kg patient, the American Thoracic Society recommends dosing as an adult rather than using pediatric weight-based calculations 22

Critical Dosing Considerations

• The American College of Chest Physicians suggests verifying that adult dosing is used for patients ≥40 kg, not pediatric weight-based calculations, to avoid dosing errors 22

Amoxicillin‑Clavulanate Dosing for Acute Bacterial Rhinosinusitis

1. First‑Line Antimicrobial Regimens

Adults (uncomplicated disease)

• Preferred regimen: Amoxicillin‑clavulanate 875 mg/125 mg taken twice daily for 5–7 days, providing ≈ 90–92 % predicted clinical efficacy against the principal pathogens. Strong recommendation. 23
• Course length: A 5–7‑day course is as effective as the traditional 10‑day regimen and results in fewer adverse effects. Moderate evidence. 23

Adults – High‑Dose Regimen (risk‑factor patients)

• Dose: Amoxicillin 2 g + clavulanate 125 mg twice daily.
• Indications: Recent antibiotic use (past 4–6 weeks), age > 65 years, daycare exposure, moderate‑to‑severe symptoms, comorbidities, or immunocompromised status.
• Efficacy: Achieves ≈ 90–92 % predicted clinical efficacy against drug‑resistant Streptococcus pneumoniae. Strong recommendation. [24][25]

Adults – Plain Amoxicillin (alternative)

• Dose: 500 mg twice daily for mild disease or 875 mg twice daily for moderate disease; duration 5–10 days.
• Use criteria: May be considered only for mild disease in patients without recent antibiotic exposure; amoxicillin‑clavulanate is generally preferred because of β‑lactamase‑producing organisms. Moderate evidence. [25][23]

Children (≥ 3 months, < 40 kg) – High‑Dose Amoxicillin‑Clavulanate (first‑line)

• Dose: 90 mg/kg/day amoxicillin component + 6.4 mg/kg/day clavulanate, divided twice daily for 10–14 days.
• Strength: Strongly recommended as the initial therapy. Strong recommendation. 23

Children – Standard‑Dose Amoxicillin (alternative for uncomplicated cases)

• Dose: 45 mg/kg/day amoxicillin component, divided twice daily; duration 10–14 days.
• Use criteria: Appropriate when disease is uncomplicated and no risk factors are present. Moderate evidence. [25][23]

Children – High‑Dose Indications (when to choose high‑dose)

• Age < 2 years, daycare attendance, recent antibiotic use (past 4–6 weeks), incomplete Hib vaccination, regional prevalence of penicillin‑resistant S. pneumoniae > 10 %, moderate‑to‑severe illness, or concurrent purulent otitis media. Strong recommendation. 23

Children – Plain Amoxicillin (alternative)

• Dose: 45 mg/kg/day (standard) or 80–90 mg/kg/day (high‑dose), divided twice daily; 10–14 days.
• Use criteria: May be used for uncomplicated cases without risk factors, but amoxicillin‑clavulanate is preferred due to β‑lactamase‑producing organisms. Moderate evidence. [25][23]

2. Clinical Reassessment

Adults

• At 3–5 days: If no clinical improvement, switch to high‑dose amoxicillin‑clavulanate or a respiratory fluoroquinolone. Strong recommendation. 23
• At 7 days: Persistent or worsening symptoms require diagnostic reconsideration, possible imaging, and ENT referral. Strong recommendation. 23

Children

• At 72 hours: Lack of improvement or clinical worsening warrants escalation to high‑dose amoxicillin‑clavulanate. Strong recommendation. 23

3. Key Prescribing Pitfalls

• Avoid antibiotics for symptom duration < 10 days unless severe features are present (fever ≥ 39 °C with purulent nasal discharge for ≥ 3 consecutive days); 98–99.5 % of acute rhinosinusitis cases are viral. Strong recommendation. 23
• Minimum treatment duration: ≥ 5 days for adults and ≥ 10 days for children to reduce relapse risk. Strong recommendation. 23
• Early reassessment (3–5 days in adults, 72 hours in children) is essential to prevent complications. Strong recommendation. 23

4. Adjunctive Therapies

• Intranasal corticosteroids (e.g., mometasone, fluticasone, budesonide) twice daily reduce mucosal inflammation and speed symptom resolution; supported by strong evidence from multiple randomized controlled trials. Strong evidence. 23
• Saline nasal irrigation 2–3 times daily provides symptomatic relief and enhances mucus clearance. Moderate evidence. 23
• Analgesics (acetaminophen or ibuprofen) for pain and fever control. Standard of care. 23

Management of Acute Bacterial Sinusitis in Patients with End‑Stage Renal Disease

Reassessment and Second‑Line Antibiotic Therapy

• If no clinical improvement is observed 3–5 days after initiating therapy (e.g., persistent purulent drainage, unchanged facial pain, or worsening), switch to a respiratory fluoroquinolone with renal‑adjusted dosing—such as levofloxacin 250 mg every 48 hours for patients with creatinine clearance < 50 mL/min. 26

Alternative Regimens for Penicillin Allergy

Non‑Severe (Non‑Type I) Allergy

• Use a second‑ or third‑generation cephalosporin with renal dose adjustment; for example, cefpodoxime 200 mg once daily for patients with creatinine clearance 10–30 mL/min. 26

Severe (Type I/Anaphylactic) Allergy

• Employ a respiratory fluoroquinolone; levofloxacin dosing for creatinine clearance 10–50 mL/min is a 500 mg loading dose followed by 250 mg every 48 hours. 26

Referral to Otolaryngology (ENT)

• Urgent ENT referral is indicated when any of the following occur:

Safety of Co‑administering Clemastine with Amoxicillin/Clavulanic Acid

Clinical Situations in Which Co‑administration Is Common

• In patients treated for acute bacterial sinusitis or pneumonia with amoxicillin/clavulanic acid, concurrent antihistamine therapy (e.g., clemastine) is frequently used to manage allergic rhinitis symptoms such as nasal congestion and rhinorrhea. 27
• The combination is also routinely employed when a bacterial upper‑respiratory infection coexists with allergic inflammation, allowing the antihistamine to address allergic symptoms while the antibiotic treats the bacterial component. 27

Safety Considerations

Sedation Risk

• Clemastine, as a first‑generation H1‑antihistamine, can cause sedation and impair performance; this sedative effect is intrinsic to the drug and is not amplified by amoxicillin/clavulanic acid. 27
• Patients should be counseled to avoid driving or operating machinery until they know how clemastine affects them, because drowsiness is a known side effect of the antihistamine itself. 27

Gastro‑intestinal Tolerability of the Antibiotic

• The clavulanic‑acid component of amoxicillin/clavulanic acid is associated with gastrointestinal adverse events (e.g., nausea, vomiting, diarrhea) in roughly 5 %– 13 % of patients, independent of any antihistamine use. 28

Alternative and Adjunctive Therapies for Amoxicillin‑Clavulanate Use

Adult Alternative Regimens

• In adults with respiratory infections, a thrice‑daily regimen of 500 mg amoxicillin + 125 mg clavulanate (total 625 mg) is an accepted alternative and is endorsed by several European guidelines. 29
• After initiating intravenous amoxicillin‑clavulanate for moderate‑to‑severe infections, clinicians should switch to the oral formulation as soon as clinical improvement is evident, typically within 48–72 hours. 29

Pediatric Alternative Regimens

• For children with mild infections and no resistance risk factors, age‑based oral suspension dosing is recommended (e.g., 0.27 mL/kg of 125/31 mg mL⁻¹ suspension three times daily for infants <1 year). 29
• In pediatric patients with moderate infections, the recommended intravenous dose is 30 mg/kg every 8 hours. 29
• For severe pediatric infections or undrained abscesses, the intravenous dose may be increased to 200 mg/kg per day divided every 6 hours (maximum 4 g/day). 29
• When a type I (anaphylactic) penicillin allergy is present, clarithromycin is used with age‑specific dosing:
  
  • < 1 year: 7.5 mg/kg twice daily
  • 1–2 years: 62.5 mg twice daily
  • 3–6 years: 125 mg twice daily
  • 7–9 years: 187.5 mg twice daily
  • ≥ 10 years: 250 mg twice daily

Allergy‑Specific Alternatives

• For adults with a type I (anaphylactic) penicillin allergy, respiratory fluoroquinolones (levofloxacin or moxifloxacin) are recommended as alternative agents. 30
• When desensitization cannot be performed in patients with type I allergy and a serious infection, vancomycin 30 mg/kg per day administered intravenously in two divided doses is advised. 30

Outpatient Parenteral Therapy

• In situations where oral therapy is unsuitable, a single daily dose of ceftriaxone 2 g given intravenously or intramuscularly provides convenient outpatient parenteral coverage. 30